Short answer
Arcellx, Inc. (ACLX) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Gilead Sciences acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, totaling up to $120.00/share.
Arcellx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Gilead Sciences acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, totaling up to $120.00/share
- CVR pays $5.00 only if anito-cel cumulative worldwide sales exceed $6.0B by December 31, 2029: milestone is high-bar, payment not guaranteed
- Two-step deal: tender offer (min 20 business days) followed by Section 251(h) back-end merger; no shareholder vote required
- Termination fee of $260M payable by Arcellx to Gilead if deal breaks under specified circumstances, limiting competing bid scenarios
- Support stockholders owning ~10.3% of shares already committed to tender, providing early deal momentum
Item 7.01 · Regulation FD Disclosure
- Arcellx merger agreement announced Feb 23, 2026 alongside FDA acceptance of BLA for anito-cel
- Anito-cel targets BCMA for relapsed/refractory multiple myeloma: BLA acceptance signals regulatory review underway
- Dual catalyst event: M&A transaction + FDA milestone disclosed simultaneously, high strategic significance for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcellx, Inc. 8-K filings
Get the next ACLX 8-K as it lands
Follow ACLX for push alerts, or ask the research agent what this filing means.